leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 17:27:14 - browse：7

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： The EU Joint Clinical Assessment needs to live up to its promise

leisure time

WSS

Change Healthcare cyberattack shows risk of industry consolidation

Readout Newsletter: Beam, Prozac, "TechBio" and more

Researchers explore possible ties between long Covid, menopause

STAT Summit: Michael J. Fox on progress in Parkinson's research

Cholera vaccine supplies dangerously low, outbreaks surging

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

hotspot

leisure time

explore

At least 13 dead in Texas as scorching temps continue

Are embryos people? Reproductive medicine's future depends on the answer

FDA approval of Sarepta Duchenne genetic therapy gives me hope

CDC panel: People 65 and older should get a Covid spring booster shot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why health workers in Gaza are injured or die at high rates

Moonlake's readout produced a cash windfall. Risks remain

Elisabeth Bik tackles the widespread issue of research misconduct

How to save PrEP access — and even expand it

Why health workers in Gaza are injured or die at high rates

explore

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

'Vaccine

First Opinion Podcast: Long Covid needs a new approach

Color Health wants to make cancer screenings convenient

Pfizer is about to make a big push in cancer. Will investors listen?

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

leisure time

Wikipedia

hotspot

Wikipedia